CCDC86 and lymphoma: Consistent with a role for CYCLON in Rituximab response in lymphoma, CYCLON depletion markedly increased the sensitivity of B593, SUDHL4 (DLBCL cell lines) and Raji (BL) lymphoma cells to Rituximab-dependent killing, particularly complement-mediated cytotoxicity (Fig 5E, F and Supporting Information Fig S5A, B).